Literature DB >> 29326317

Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.

Randy C Bowen1, Andrew Xingyu Zhou2, Sailaja Bondalapati2, Thomas W Lawyer2, Karisa B Snow3, Patrick R Evans2, Tyler Bardsley2, Mary McFarland2, Matthew Kliethermes2, Dallas Shi2, Christina A Mamalis2, Tom Greene2, Christopher J Rudnisky4, Balamurali Krishna Ambati2.   

Abstract

BACKGROUND: Current practice methods are unclear as to the most safe and effective prophylactic pharmacotherapy and method of delivery to reduce postoperative endophthalmitis occurrence.
METHODS: A systematic review and meta-analysis using Meta-analysis of Observational Studies in Epidemiology guidelines was performed to compare the efficacy of intracameral cefuroxime, moxifloxacin and vancomycin in preventing postphacoemulsification cataract surgery endophthalmitis. A safety analysis of intracameral antibiotics was concurrently performed. DATA SOURCES: BIOSIS Previews, CINAHL, ClinicalTrials.gov, Cochrane Library, Dissertations & Theses, EMBASE, PubMed, ScienceDirect and Scopus were searched from inception to January 2017. Data were pooled using a random effects model. All articles were individually reviewed and data were extracted by two independent reviewers. Funnel plot, risk of bias and quality of evidence analyses were performed.
RESULTS: Seventeen studies with over 900 000 eyes were included, which favoured the use of intracameral antibiotics at the end of cataract surgery (OR 0.20; 95% CI 0.13 to 0.32; P<0.00001). The average weighted postoperative endophthalmitis incidence rates with intracameral cefuroxime, moxifloxacin and vancomycin were 0.0332%, 0.0153% and 0.0106%, respectively. Secondary analyses showed no difference in efficacy between intracameral plus topical antibiotics versus intracameral alone (P>0.3). Most studies had low to moderate risk of bias. The safety analysis showed minimal toxicity for moxifloxacin. Dosing errors led to the majority of toxicities with cefuroxime. Although rare, vancomycin was associated with toxic retinal events.
CONCLUSION: Intracameral cefuroxime and moxifloxacin reduced endophthalmitis rates compared with controls with minimal or no toxicity events at standard doses. Additionally, intracameral antibiotics alone may be as effective as intracameral plus topical antibiotics. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drugs; infection; treatment medical; treatment surgery

Mesh:

Substances:

Year:  2018        PMID: 29326317      PMCID: PMC6041193          DOI: 10.1136/bjophthalmol-2017-311051

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  74 in total

1.  Macular thickness after cataract surgery with intracameral cefuroxime.

Authors:  Mamta S Gupta; Hamish D R McKee; Manuel Saldaña; Owen G Stewart
Journal:  J Cataract Refract Surg       Date:  2005-06       Impact factor: 3.351

2.  Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.

Authors:  Lisa Brothers Arbisser
Journal:  J Cataract Refract Surg       Date:  2008-07       Impact factor: 3.351

3.  [Using intracameral cefuroxime reduces postoperative endophthalmitis rate: 5 years experience at the University Eye Hospital Tübingen].

Authors:  T Röck; M Bramkamp; K-U Bartz-Schmidt; U Mutlu; E Yörük; D Röck; S Thaler
Journal:  Klin Monbl Augenheilkd       Date:  2014-10-21       Impact factor: 0.700

4.  Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery.

Authors:  Marie-Noëlle Delyfer; Marie-Bénédicte Rougier; Sandy Leoni; Qiuhua Zhang; Francis Dalbon; Joseph Colin; Jean-François Korobelnik
Journal:  J Cataract Refract Surg       Date:  2011-02       Impact factor: 3.351

5.  Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis.

Authors:  Christopher J Rudnisky; Darwin Wan; Ezekiel Weis
Journal:  Ophthalmology       Date:  2013-12-08       Impact factor: 12.079

6.  Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes.

Authors:  T M Aaberg; H W Flynn; J Schiffman; J Newton
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

7.  Intracameral vancomycin following cataract surgery: An eleven-year study.

Authors:  Deepa R Anijeet; Prasad Palimar; Clive O Peckar
Journal:  Clin Ophthalmol       Date:  2010-04-26

8.  Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.

Authors:  Su-Young Kim; Young-Hoon Park; Young-Chun Lee
Journal:  Clin Exp Ophthalmol       Date:  2008-05       Impact factor: 4.207

9.  Incidence of Acute Postoperative Endophthalmitis after Cataract Surgery: A Nationwide Study in France from 2005 to 2014.

Authors:  Catherine Creuzot-Garcher; Eric Benzenine; Anne-Sophie Mariet; Aurélie de Lazzer; Christophe Chiquet; Alain M Bron; Catherine Quantin
Journal:  Ophthalmology       Date:  2016-03-16       Impact factor: 12.079

10.  Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use.

Authors:  Efdal Yoeruek; Martin S Spitzer; Oguzhan Saygili; Olcay Tatar; Tilo Biedermann; Erdal Yoeruek; Karl U Bartz-Schmidt; Peter Szurman
Journal:  J Cataract Refract Surg       Date:  2008-12       Impact factor: 3.351

View more
  18 in total

1.  [Endophthalmitis].

Authors:  Thomas Neß
Journal:  Ophthalmologe       Date:  2018-08       Impact factor: 1.059

2.  Reduced Posology of an Ophthalmic Hydrogel Containing Dexamethasone/Netilmicin to Prevent and Treat Ocular Inflammation After Cataract Surgery: Efficacy and Tolerability.

Authors:  Rita Mencucci; Thomas Ach; Anja Liekfeld; Antonio Scialdone; Claudine Civiale; Maria Grazia Mazzone; Aldo Caporossi
Journal:  Adv Ther       Date:  2022-10-07       Impact factor: 4.070

3.  Evaluation of the effect of gentamicin in surgical perfusion solution on cataract postoperative endophthalmitis.

Authors:  Wenjiang Ma; Guanghua Hou; Junfang Wang; Ting Liu; Fang Tian
Journal:  BMC Ophthalmol       Date:  2022-10-23       Impact factor: 2.086

4.  Endophthalmitis prophylaxis study. Report 1: Intracameral cefuroxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India.

Authors:  Varsha M Rathi; Savitri Sharma; Taraprasad Das; Rohit C Khanna
Journal:  Indian J Ophthalmol       Date:  2020-05       Impact factor: 1.848

Review 5.  A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment.

Authors:  Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

Review 6.  The Routine Use of Intracameral Antibiotics to Prevent Endophthalmitis After Cataract Surgery: How Good is the Evidence?

Authors:  Nicholas K George; Michael W Stewart
Journal:  Ophthalmol Ther       Date:  2018-07-05

7.  Microbiological Isolates and Antibiotic Susceptibilities in Cases of Posttraumatic Endophthalmitis: A 15-Year Review.

Authors:  Chunhong Liu; Jian Ji; Zhujian Wang; Huiwen Chen; Wenjun Cao; Xinghuai Sun
Journal:  J Ophthalmol       Date:  2020-04-29       Impact factor: 1.909

8.  Endophthalmitis following cataract surgery and intracameral antibiotic: Moxifloxacin resistant Staphylococcus epidermidis.

Authors:  Victoria S Chang; Stephen G Schwartz; Janet L Davis; Harry W Flynn
Journal:  Am J Ophthalmol Case Rep       Date:  2018-12-08

9.  Intraoperative Cefuroxime Irrigation Prophylaxis for Acute-Onset Endophthalmitis After Phacoemulsification Surgery.

Authors:  Xiubin Ma; Lixin Xie; Yusen Huang
Journal:  Infect Drug Resist       Date:  2020-05-18       Impact factor: 4.003

10.  Unilateral acute iris depigmentation and transillumination after glaucoma surgery with mitomycin application and intracameral moxifloxacin.

Authors:  Carmen Sánchez-Sánchez; Beatriz Puerto; Cristina López-Caballero; Inés Contreras
Journal:  Am J Ophthalmol Case Rep       Date:  2020-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.